HPS3/TIMI 55 REVEAL assessed the effect of cholesterol ester transfer protein (CETP) inhibition with anacetrapib 100 mg versus matching placebo on time to first major coronary event among 30,000 individuals with pre-existing vascular disease. MAIN RESULTS: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease N Engl J Med. 2017 Sep 28;377(13):1217-1227. PRESENTATIONS ESC 2017 … Continue reading HPS3/TIMI 55 REVEAL